source
- Novo Holdings backs European fund; Alnylam sends second obesity drug into clinicPlus news about IMU Biosciences, Autobahn and Jade Biosciences. 💸 Novo Holdings invests in Europe-focused fund: The investment manager of the Novo Nordisk Foundation's fortunes is backing the Scal…Endpoints · 1mo ago↗ source
- Alnylam, Inceptive ink AI deal potentially worth $2BThe RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.BioPharma Dive · 1mo ago↗ source
- An ADC specialist sinks on safety concerns for blood cancer drugShares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”